This decision was informed by three new Addyi alcohol interaction studies which demonstrated no syncope or orthostatic hypotension requiring medical attention. This data has been presented to the International Society for the Study of Women's Sexual Health, International Society for Sexual Medicine and Sexual Medicine Society of North America and was submitted to the FDA eight months ago.
Sprout received the FDA ordered Addyi labeling change to lessen the alcohol restriction on April 11, 2019.
The label change, once implemented, will ensure that healthcare providers and patients alike have confidence to make accurate, informed treatment decisions with study findings.
Sprout Pharmaceuticals has chosen to continue discussions with the FDA to ensure all elements of labeling are equally in line with all known scientific data through a standard appeal process.
This includes the now, inconsistent REMS program that requires healthcare providers and pharmacies to be certified to prescribe or dispense Addyi and women to sign a consent they will not drink when given a prescription for the drug.
Sprout Pharmaceuticals is focused solely on the delivery of a treatment option for women with HSDD.
Addyi is the first and only FDA-approved treatment for acquired, generalised hypoactive sexual desire disorder for premenopausal women.
In clinical trials, Addyi has demonstrated improvements in desire for sex, reducing distress from the loss of sexual desire and increasing the number of satisfying sexual events.
The most common adverse events among patients treated with Addyi were dizziness, somnolence, nausea, fatigue, insomnia and dry mouth.
Hypotension, syncope, and central nervous system depression were seen with Addyi alone and more frequently when co-administered with alcohol in the morning, or certain other drugs. Alcohol consumption within two hours of taking Addyi is contraindicated.
With the FDA, Sprout Pharmaceuticals developed a comprehensive Risk Evaluation and Mitigation Strategy program, including prescriber and pharmacist certification, to ensure safe use of Addyi.
Addyi is a novel, non-hormonal oral pill to be taken at bedtime.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial